Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biotech Growth Trust (The)LSE:BIOG +0.74%37 Cyclically Adjusted PS Ratio is 16.92 as of Jul. 26, 2026, which is 50% above its 10-year median of 11.31. GuruFocus rates LSE:BIOG with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 906 Asset Management companies, Biotech Growth Trust (The) ranks worse than 83.66% on this metric.
The historical rank and industry rank for Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio or its related term are showing as below:
LSE:BIOG'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.44 Med: 11.31 Max: 142.78
Current: 16.96
During the past 13 years, Biotech Growth Trust (The)'s highest Cyclically Adjusted PS Ratio was 142.78. The lowest was 6.44. And the median was 11.31.
LSE:BIOG's Cyclically Adjusted PS Ratio is ranked worse than 83.66% of 906
companies
in the Asset Management industry
Industry Median: 7.675
vs LSE:BIOG: 16.96
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Biotech Growth Trust (The)'s adjusted revenue per share data of for the fiscal year that ended in Mar26 was £5.735. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is £0.96 for the trailing ten years ended in Mar26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Biotech Growth Trust (The) (LSE:BIOG) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Biotech Growth Trust (The) Cyclically Adjusted PS Ratio Related Terms
Biotech Growth Trust (The) Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotech Growth Trust (The) Cyclically Adjusted PS Ratio Chart
LSE:BIOG vs BLK, BX, KKR: Cyclically Adjusted PS Ratio Comparison
For the Asset Management subindustry, Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotech Growth Trust (The) Cyclically Adjusted PS Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio falls into.
Biotech Growth Trust (The) Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 16.92 mean?
Biotech Growth Trust (The) (LSE:BIOG) has a Cyclically Adjusted PS Ratio of 16.92 as of Jul. 26, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotech Growth Trust (The) and its competitors. This is 50% above median its historical median of 11.31. Over the past decade, Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio has ranged from 6.44 to 142.78. According to the industry distribution chart, Biotech Growth Trust (The) ranks #758 out of 906 companies in the Asset Management industry, placing it in the top 83.7%.
Is Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio too high?
Biotech Growth Trust (The)'s current Cyclically Adjusted PS Ratio of 16.92 is 50% above median its 10-year median of 11.31. Over the past 10 years, this metric has ranged from a low of 6.44 to a high of 142.78. The Asset Management industry median Cyclically Adjusted PS Ratio is 7.68. Biotech Growth Trust (The)'s value of 16.92 is 120.5% above this industry median. Based on the distribution chart, Biotech Growth Trust (The) ranks #758 out of 906 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, Biotech Growth Trust (The) has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio compare to BLK and BX?
According to the Asset Management industry distribution chart, Biotech Growth Trust (The) ranks #758 out of 906 companies for Cyclically Adjusted PS Ratio. This places Biotech Growth Trust (The) in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 7.68. Biotech Growth Trust (The)'s value of 16.92 is 120.5% above this benchmark. Historically, Biotech Growth Trust (The)'s own Cyclically Adjusted PS Ratio has ranged from 6.44 to 142.78 over the past decade. While the company's 10-year median is 11.31 vs. the industry median of 7.68, Biotech Growth Trust (The) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for an Asset Management company?
The median Cyclically Adjusted PS Ratio among Asset Management companies is 7.68, based on 906 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotech Growth Trust (The)'s current Cyclically Adjusted PS Ratio of 16.92 is 120.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotech Growth Trust (The) and its competitors. For the Asset Management industry, the median Cyclically Adjusted PS Ratio is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotech Growth Trust (The)'s current Cyclically Adjusted PS Ratio is 16.92, which is 50% above median its own 10-year median of 11.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotech Growth Trust (The) stock overvalued right now?
Biotech Growth Trust (The) (LSE:BIOG) has a current Cyclically Adjusted PS Ratio of 16.92. The current Cyclically Adjusted PS Ratio is 16.92, which is 50% above median its 10-year median of 11.31 and 120.5% above the Asset Management industry median of 7.68. Biotech Growth Trust (The)'s overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Biotech Growth Trust (The) (LSE:BIOG), the current Cyclically Adjusted PS Ratio is 16.92 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotech Growth Trust (The) PLC is an externally managed investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world.
37GF Score
Get the complete analysis for LSE:BIOG
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BIOG has been successfully added to your 
